pH Associates to present 3 Real World Evidence posters at ASH!

Written on Monday 4th December 2017

pH Associates (An OPEN Health company) are proud to have 3 posters presented at the 59th American Society of Haematology (ASH) Annual meeting, taking place from 9 - 12th December 2017 – showing the ever increasing value of Real World Evidence to the scientific community.

The 59th ASH Annual Meeting & Exposition is a premier event in the malignant and non-malignant haematology calendar. pH Associates are proud to have 3 posters at the 59th American Society of Haematology (ASH) annual meeting  – showing the ever increasing value of Real World Evidence to the scientific community. Visit the links below to view pH's accepted abstracts:-

Age (≤75 years) and Not Choice of First-line Therapy Improves Overall Survival in Transplant Ineligible NDMM Patients: Results from a Large UK Real-World Dataset https://ash.confex.com/ash/2017/webprogram/Paper104582.html

Inferior Clinical Outcomes with Fixed-Duration Therapy for Transplant-Ineligible Myeloma Patients: UK Real-World Data in Comparison with the FIRST Trial (MM-020) https://ash.confex.com/ash/2017/webprogram/Paper102232.html

The TARGET UK Study: real-world evidence of molecular response to tyrosine kinase inhibitors supports European LeukemiaNet 2013 recommendations for the management of Chronic Myeloid Leukemia https://ash.confex.com/ash/2017/webprogram/Paper105390.html

For further details about pH Associates (an OPEN Health company) and its Real World Evidence offerings, please contact Samantha Oliver or Amanda Pulfer, Joint Managing Directors at pH Associates either via email: SamanthaOliver@phassociates.comAmandaPulfer@phassociates.com, or telephone: 01628 897 968